title: [5'-DFUR chemoprophylaxis in superficial bladder cancer. Kanagawa Urology 5'-DFUR Study Group].
abstract: 5'-Deoxy-5-fluorouridine (5'-DFUR), an oral fluorinated pyrimidine carbamate, is widely used in patients with gastrointestinal and breast cancers because of its effectiveness. However, in bladder cancer, response rates have only been reported in Phase II clinical trials. Therefore, we conducted a prospective randomized trial to investigate chemoprophylactic effect of 5'-DFUR against recurrence of superficial bladder cancer after transurethral bladder tumor resection (TUR-Bt). The subjects were grouped as follows: 1) 5'-DFUR group (n = 31), received 600 mg/day of 5'-DFUR starting 2-3 weeks after TUR-Bt for 2 years; and 2) control group (n = 31) received no 5'-DFUR. Although there was no significant difference between groups, the cumulative recurrence rates was more favorable in the 5'-DFUR group (p = 0.256) than in the controls. Results according to cancer factors showed that, in patients with G2 based on grading, those in the 5'-DFUR group tended to have a lower recurrence rate than the control group (p = 0.070). There was a 40% incidence of adverse drug reactions (12/30 patients), primarily slight gastrointestinal symptoms which disappeared or improved with drug discontinuation. The results of the present study suggest that 5'-DFUR might be the choice of treatment to prevent recurrence of superficial bladder cancer.
authors.affiliation: Department of Urology, Yokohama City University School of Medicine.
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: M
authors.initials: M
authors.lastname: Masuda
authors.forename: M
authors.initials: M
authors.lastname: Hosaka
authors.forename: K
authors.initials: K
authors.lastname: Noguchi
authors.forename: K
authors.initials: K
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Miura
authors.forename: I
authors.initials: I
authors.lastname: Ikeda
authors.forename: I
authors.initials: I
authors.lastname: Kondo
authors.forename: Y
authors.initials: Y
authors.lastname: Senga
authors.forename: M
authors.initials: M
authors.lastname: Moriyama
authors.forename: S
authors.initials: S
authors.lastname: Fukushima
authors.forename: T
authors.initials: T
authors.lastname: Ebato
authors.forename: M
authors.initials: M
authors.lastname: Fukuda
authors.forename: K
authors.initials: K
authors.lastname: Kitami
authors.forename: H
authors.initials: H
authors.lastname: Fukuoka
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: M
authors.initials: M
authors.lastname: Hirokawa
authors.forename: K
authors.initials: K
authors.lastname: Chiba
authors.forename: H
authors.initials: H
authors.lastname: Kanno
authors.forename: K
authors.initials: K
authors.lastname: Miyai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007536:Isomerism; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine; C025034:doxifluridine